SATB2相关综合征临床实践指南主题优先排序:方法学严谨性与临床可用性的权衡
欧洲参考网络ITHACA与患者社区合作制定SATB2相关综合征指南,通过社区调查收集376个主题并精炼为48个,269名有效应答者参与在线优先排序。核心组最终未按原计划选定12个各配系统评价的主题,而改为22个问题仅配1篇系统评价,认为指南完整性与临床可用性应优先于方法学严谨性。
要点
- 社区驱动的优先排序将376个原始主题合并精炼为48个临床主题。
- 269名有效应答者参与在线排序,其中234人为代表/家庭/照护者,30人为临床医生。
- 核心组最终确定22个问题而非12个,且仅开展1篇系统评价。
核心结论
- 尽管采用严谨的社区驱动流程,指南核心组仍无法就12个临床主题达成一致。
- 核心组认为指南的完整性与临床可用性应优先于严格遵循12个各配系统检索的主题。
- 完整性与可用性同方法学严谨性在罕见病临床实践指南制定中是相互竞争的利益,目前尚无明确解决方案。
研究设计与样本
- 欧洲参考网络ITHACA与患者社区紧密合作制定SATB2相关综合征临床实践指南。
- 优先排序流程旨在基于事先定义的标准将相关临床问题缩减至最多12个。
- 流程包括SAS社区范围调查、使用工具计算最多投票条目的优先排序轮次,以及与指南核心组的最终共识轮次。
主要发现
- 第一轮基于超过20个家庭的输入共收集376个主题,合并精炼为48个临床主题。
- 269名有效应答者在线填写优先排序,其中234人为代表/家庭/照护者,30人为临床医生,5人兼具两种身份。
- 核心组最终决定22个问题,仅1篇系统评价,而非12个各配系统评价的主题。
关键数值与推荐
- 优先排序目标为基于事先定义标准将相关临床问题缩减至最多12个。
- 原始收集376个主题,合并精炼为48个临床主题。
- 核心组最终确定22个问题,仅开展1篇系统评价。
临床怎么用
- 罕见病指南制定中,社区广泛参与的主题收集与优先排序有助于识别患者和临床医生最关切的问题。
- 当严格方法学要求与指南完整性冲突时,核心组可选择扩大问题范围但减少系统评价数量。
局限性
- 核心组未能就12个临床主题达成共识,偏离了预设的优先排序目标。
- 最终22个问题仅配1篇系统评价,指南推荐所依据的系统检索证据较少。
- 完整性与可用性同方法学严谨性的竞争问题在罕见病指南制定中尚无明确解决方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SATB2-associated syndrome (SAS) is a rare genetic condition characterized by developmental delay and typical features. Currently, an evidence-based clinical practice guideline (CPG) is being developed by European Reference Network ITHACA in close collaboration with the patient community. To ensure that the guideline addresses the most pressing concerns of affected individuals, families, and clinicians, while remaining feasible to produce, a prioritization process was carried out. STUDY DESIGN AND SETTING: The prioritization process aimed to minimize the relevant clinical questions to a maximum of 12, based on criteria that were defined beforehand and based on input from a large patient community. The prioritization process included a SAS community-wide survey that collected all patient-relevant topics, a prioritization round using a tool that helps to calculate the items that were most voted on, and a final consensus round with the guideline core group. RESULTS: In the first round, a total of 376 topics was collected based on input from over 20 families. These were combined and refined into 48 clinical topics. A total of 269 valid responders filled in their prioritization on these topics in an online survey. Of these respondents, 234 identified as representative/family/carer, 30 identified as clinician, and 5 individuals identified as both. Rather than prioritizing a subset of 12 topics, that each would be answered with a systematic review, the core group decided on a final set of 22 questions and only 1 systematic review. CONCLUSION: Despite using a rigorous, community-driven process with input from many parents, carers, and global clinical experts, the guideline core group could not agree on a final set of 12 clinical topics. The group concluded that completeness and clinical usability of the guideline should take precedence over adhering to 12 prioritized clinical topics that could each be answered with a systematic search in the literature. We concluded that completeness and usability, vs methodological rigor, are competing interests in CPG development. This methodological issue is a pressing matter in the field of rare disease CPG development, and possibly also beyond the context of rare diseases, for which no clear solution currently exists. PLAIN LANGUAGE SUMMARY: SATB2-associated syndrome (SAS) is a rare genetic condition that causes developmental delays and other characteristic features. A new clinical practice guideline (CPG) for SAS is currently being developed by the European Reference Network ITHACA, together with families, caregivers, and health-care professionals. To make sure the guideline focuses on the most important needs of the SAS community, a structured process was used to decide which clinical topics should be included. First, families across the SAS community were asked to share their concerns. This resulted in 376 topics, which were combined into 48 broader clinical themes. Next, 269 people completed an online survey to rank these topics. Most respondents were family members or caregivers, and some were clinicians. Finally, the guideline development team reviewed the results and discussed which topics should be prioritized. Although the original goal was to select 12 questions to answer through systematic reviews, the team decided that limiting the guideline to only 12 topics would leave out important issues. Instead, they agreed on 22 key questions, which would be addressed with only 1 systematic review. The CPG recommendations would then be more complete but supported with less systematically searched evidence. This experience highlights an ongoing challenge in rare disease guideline development: balancing completeness and practicality with strict methodological standards.
引用
- Gaasterland CMW, Klein Haneveld MJ, Tinselboer BM, et al. Prioritizing topics for a clinical practice guideline on SATB2-associated syndrome: methodological rigor vs clinical usability. J Clin Epidemiol. 2026. PMID: 41722828. doi:10.1016/j.jclinepi.2026.112187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。